Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal

AbbVie ($ABBV) can count this among the consequences of canceling its Shire ($SHPG) buyout: Deal-focused hedge funds are losing investors.

The M&A event funds had been riding high, with last year as their best since 2010. But a spate of failed mergers--AbbVie and Shire's in particular--has prompted investors to withdraw their funds, spurring hedge funds to be a bit more cautious.

A combination of low interest rates, weak global growth and cash-rich companies got the year off to a promising start. But as a result of AbbVie and Shire's $55 billion collapse, and a handful of other no-go transactions, investors have pulled out $3.3 billion in the last two months alone, Reuters reports.

"The AbbVie-Shire break, in particular, has led to a far reaching de-risking exercise for many funds," Pierre di Maria, head of event driven strategy at Cheyne Capital, told the news service. "Those funds have reduced their gross exposure to deals in order to lessen their overall risk and to be able to face any upcoming redemptions."

Liongate Capital Management Managing Director Jeff Holland

In particular, managers are becoming more conscious of political risk and intervention--the kind that sunk the AbbVie-Shire transaction--in the M&A arena, Jeff Holland, a managing director at hedge fund investor Liongate Capital Management, told Reuters. The Abbott spinoff blamed stricter U.S. rules on tax inversion moves--the kind it hoped to complete after picking up Ireland-based Shire--for scuttling the deal.

And at least one hedge fund manager is thinking about striking back in the form of litigation, the New York Post reported last week. Billionaire Paul Singer, founder and CEO of Elliott Management, told investors in a letter that he was considering suing AbbVie for "making false and misleading statements about the transaction."

Elliott Management CEO Paul Singer

But Singer's Elliott didn't even take that bad a blow compared with some of its peers. Hedge fund manager John Paulson, who socked £1.44 billion pounds into Shire shares in October, watched his Advantage fund lose 13.6% in October, one investor told Reuters. And the $1.4 billion Tyrus Capital Event Fund closed out that month down about 6.5% after Tyrus Capital bet on both Shire's share price climbing and AbbVie's sinking.

- read the Reuters news

Special Reports: Top 15 highest-paid biopharma CEOs of 2013 - Richard Gonzalez, AbbVie | Pharma's top 10 M&A deals of 2014's first half

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.